Earnings call: Genus reports progress amid market challenges, eyes FDA approval
Genus PLC reported FY 2024 revenue of GBP669 million and adjusted operating profit of GBP78.1 million, with strategic progress in porcine and bovine businesses. Despite profit declines, the company maintained a steady dividend and expects significant growth in FY 2025, anticipating FDA approval for its gene-edited pig in 2025.
Highlighted Terms
Related News
Earnings call: Genus reports progress amid market challenges, eyes FDA approval
Genus PLC reported FY 2024 revenue of GBP669 million and adjusted operating profit of GBP78.1 million, with strategic progress in porcine and bovine businesses. Despite profit declines, the company maintained a steady dividend and expects significant growth in FY 2025, anticipating FDA approval for its gene-edited pig in 2025.